TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
TScan Therapeutics's total debt was $32.78M at Jun 30, 2026. For fiscal 2025 it was $32.53M, up 1.4% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.53M | +1.4% |
| FY2024 | Dec 31, 2024 | $32.07M | +6.7% |
| FY2023 | Dec 31, 2023 | $30.05M | +2.6% |
| FY2022 | Dec 31, 2022 | $29.29M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $32.78M | +1.5% |
| Q1 FY2026 | Mar 31, 2026 | $32.65M | +1.5% |
| Q4 FY2025 | Dec 31, 2025 | $32.53M | +1.4% |
| Q3 FY2025 | Sep 30, 2025 | $32.41M | +5.8% |
| Q2 FY2025 | Jun 30, 2025 | $32.30M | +6.1% |
| Q1 FY2025 | Mar 31, 2025 | $32.18M | +6.4% |
| Q4 FY2024 | Dec 31, 2024 | $32.07M | +6.7% |
| Q3 FY2024 | Sep 30, 2024 | $30.65M | +2.3% |
| Q2 FY2024 | Jun 30, 2024 | $30.45M | +2.4% |
| Q1 FY2024 | Mar 31, 2024 | $30.25M | +2.5% |
| Q4 FY2023 | Dec 31, 2023 | $30.05M | +2.6% |
| Q3 FY2023 | Sep 30, 2023 | $29.95M | +3.0% |
| Q2 FY2023 | Jun 30, 2023 | $29.72M | – |
| Q1 FY2023 | Mar 31, 2023 | $29.50M | – |
| Q4 FY2022 | Dec 31, 2022 | $29.29M | – |
| Q3 FY2022 | Sep 30, 2022 | $29.07M | – |
See a number that looks wrong?